#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Kearns-Sayre syndrome Cerebral amyloid angiopathy Acute graft versus host disease in liver Albright's disease Ventricular tachycardia Palmar-plantar erythrodysaesthesia syndrome Muscular dystrophy Craniocerebral injury Herpes simplex Hormone-dependent prostate cancer Astrocytoma malignant Acute lymphocytic leukaemia recurrent Infantile apnoea Ocular lymphoma Indolent systemic mastocytosis More trials…

    Learn about Rare Diseases

    Phenylketonuria – Treatment Primary hyperoxaluria – Treatment Indolent systemic mastocytosis – Treatment Combined immunodeficiency Fragile X syndrome – Trials in Disease Myelodysplastic syndrome with excess blasts – Basic Information Biotinidase deficiency – Trials in Disease Mantle cell lymphoma stage III Alport’s syndrome – Life with Disease Prolymphocytic leukaemia – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Avapritinib Azacitidine Vibostolimab PIPOTIAZINE Pemigatinib Omeprazole Csm-Gw Nifedipine Infliximab Imipenem Loncastuximab Tesirine ABBV-CLS-628 Betamethasone Acetate Elafibranor Fadraciclib GT-002 Haloperidol Epacadostat Amiloride Hydrochloride Xevinapant More therapies…

    Learn about Your Condition

    Herpes simplex reactivation Follicular lymphoma stage III Myocarditis post infection Macular degeneration Plasmablastic lymphoma Hot flush Gastric cancer recurrent Exudative retinopathy Hepatic fibrosis Renal injury Coronary artery disease Dyspnoea Toxic epidermal necrolysis Lupus nephritis Addison's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Peritoneal cancer index

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Fallopian tube cancer
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Cemiplimab
    • Sarilumab
    • Tocilizumab
    Belgium France Italy The Netherlands Spain

  • Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Ovarian cancer
    • Peritoneal cancer index
    Investigated Drugs:
    • Niraparib
    • Dostarlimab
    • Bevacizumab
    Czechia France Germany Italy

  • Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Ovarian cancer recurrent
    • Peritoneal cancer index
    Investigated Drugs:
    • Cemiplimab
    • Fianlimab
    • Regn5668
    Belgium France Spain

  • Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Ovarian cancer
    • Peritoneal cancer index
    Investigated Drugs:
    • Nemvaleukin Alfa
    • Topotecan Hydrochloride
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark France Germany +4

  • Study of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Ovarian cancer recurrent
    • Peritoneal cancer index
    Investigated Drugs:
    • Pembrolizumab
    Germany

  • Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Peritoneal cancer index
    Investigated Drugs:
    • Mk-4830
    • Bevacizumab
    • Carboplatin
    Belgium Italy Poland Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!